Neuroendocrine Cancer Awareness

  • Sorry, I'm not in service

    This has been submitted as a guest blog by the Community Team.  Thanks to Jess for the highlight!

    You can read it here:  https://community.macmillan.org.uk/blogs/b/community_news/archive/2015/08/11/guest-post-sorry-i-m-not-in-service

  • I look well but you should see my insides

    I'm sat next to patients waiting on their chemotherapy treatment - the "Chemo Ward" sign above the door gives it away.  I'm here for my 28 day cycle injection of Lanreotide which will hopefully keep my Neuroendocrine Tumours at bay. I look all around, the temporary beds and the waiting room are full and all I can see is people who don't look very well.

    No matter how many visits I make, I can't help feeling…

  • I'll still here

    Five years ago today I was diagnosed with metastatic Neuroendocrine Cancer.  Until recently, I hadn’t thought much about what this actually meant and how (or if) I should mark the occasion.  I’ve concluded there doesn’t seem to be a right or wrong way to handle these type of milestones, frequently referred to as ‘Cancerversaries‘. I’ll therefore settle for a blog!

    I don’t tend to…

  • Neuroendocrine Cancer Nutrition Blog 2 - Malabsorption

    This is the second blog in the Neuroendocrine Cancer Nutrition series.  In Blog 1, I focussed on Vitamin and Mineral deficiency risks for patients. Those who remember the content will have spotted the risks pertaining to the inability to absorb particular vitamins and minerals.  This comes under the general heading of Malabsorption and in Neuroendocrine Cancer patients, this can be caused or exacerbated by one or more of…

  • Neuroendocrine Cancer - not as rare as you think

    We expected that about 1 percent of

    Background

    Although initially considered rare tumours up until 10 years ago, the most recent data indicates the incidence of NETs has increased exponentially over the last 4 decades and they are as common as Myeloma, Testicular Cancer, and Hodgkin’s Lymphoma. In terms of prevalence, NETs represent the second commonest gastrointestinal malignancy after colorectal cancer.

    In fact, the graph of the SEER database…